AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal
Executive Summary
AbbVie posts solid quarter on strength of Skyrizi growth and continued US growth for Humira ahead of patent expiry. Imbruvica revenue continues to decline, however.